Revolution Medicines, Inc. Warrant (RVMDW)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Revolution Medicines, Inc. (NASDAQ:RVMDW) Short Interest Update
Revolution Medicines, Inc. (NASDAQ: RVMDW - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,369 shares, an increase of 138.9% from the February 12th total of 573 shares. Based on an average daily trading volume, of 11,580
Revolution Medicines, Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 13.72M | $24.39M | $85.92M | $61.53M | 252.23% |
 John H. Burbank III Passport Capital LLC | 9.56M | $17.1M | $59.82M | $42.71M | 249.72% |
| AS Alexandra Stickelman Root Financial Partners, LLC | 212 | $115.62 | $1,327.12 | $1,211.5 | 1,047.8% |
| CH Courtney Holt Compound Planning, Inc. | 2,313 | $4,140.27 | $14,479.38 | $10,339.11 | 249.72% |
| TM Tony Macafee UniSuper Management Pty Ltd | 2,800 | $5,012 | $17,528 | $12,516 | 249.72% |
Revolution Medicines, Inc. Warrant (RVMDW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revolution Medicines, Inc. Warrant ever had a stock split?
Revolution Medicines, Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Goldsmith CEO | NASDAQ (NGS) Exchange | 76155X100 CUSIP |
| US Country | 616 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company dedicated to developing innovative targeted therapies for RAS-addicted cancers. These cancers are notoriously difficult to treat due to mutations in the RAS genes, which are among the most common in cancer. Established in 2014 and based in Redwood City, California, Revolution Medicines focuses on creating RAS(ON) inhibitors and companion inhibitors. These therapies are being designed for monotherapy use, in combination with other RAS(ON) inhibitors, and/or in combination with therapeutic agents, aiming to offer new hope for patients with few existing treatment options.
Products and Services
- RAS(ON) Inhibitors
Revolution Medicines is pioneering the charge against RAS-addicted cancers with its line of RAS(ON) inhibitors. These include:
- RMC-6236 (multi): A versatile inhibitor currently under phase 1 clinical trial.
- RMC-6291 (G12C): Specifically targeting the G12C mutation, this inhibitor is also in phase 1 clinical trials.
- RMC-9805 (G12D): Focused on combating the G12D mutation, it is undergoing phase 1 clinical trials as well.
- RAS Companion Inhibitors
To complement its RAS(ON) inhibitors, Revolution Medicines is developing RAS companion inhibitors, which are designed for combination treatment strategies to enhance the efficacy of its primary inhibitors. Among them are:
- RMC-4630: Currently in phase 2 clinical trials, it holds promise for effective combination therapies.
- RMC-5552: This is in phase 1 clinical trials and is part of the company's efforts to broaden the scope of potential treatment combinations.
